All In Biotech

Investigational drug · Phase 2

NRC-2694-A

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Phase 2

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "NRC-2694-A"

First trial start

2022

Sep 30, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "NRC-2694-A", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Carcinoma
  • Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Approved drugs for the same conditions: Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "NRC-2694-A" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Carcinoma

  • Savolitinibhmpl-504, AZD6094Phase 311 trials

    AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer

  • STAR0602InvikafuspPhase 22 trials

    Marengo Therapeutics, Inc. · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumors

  • KVA12123Phase 21 trial

    Kineta Inc. · Cancer, Solid Tumor, Melanoma

  • ST-067Phase 21 trial

    Simcha IL-18, Inc. · Cancer, Solid Tumor, Melanoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.